1832 Asset Management L.P. Makes New Investment in Medpace Holdings, Inc. (NASDAQ:MEDP)

1832 Asset Management L.P. bought a new position in Medpace Holdings, Inc. (NASDAQ:MEDP) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 17,100 shares of the company’s stock, valued at approximately $6,911,000. 1832 Asset Management L.P. owned about 0.06% of Medpace as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Rise Advisors LLC purchased a new position in Medpace in the first quarter worth about $27,000. Mather Group LLC. bought a new position in shares of Medpace in the first quarter worth about $28,000. GAMMA Investing LLC bought a new position in shares of Medpace in the fourth quarter worth about $30,000. Fidelis Capital Partners LLC bought a new position in shares of Medpace in the first quarter worth about $31,000. Finally, McGlone Suttner Wealth Management Inc. bought a new position in shares of Medpace in the fourth quarter worth about $33,000. 77.98% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CEO August J. Troendle sold 15,102 shares of Medpace stock in a transaction that occurred on Monday, April 29th. The stock was sold at an average price of $400.69, for a total value of $6,051,220.38. Following the completion of the transaction, the chief executive officer now owns 791,541 shares in the company, valued at approximately $317,162,563.29. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, CEO August J. Troendle sold 5,695 shares of Medpace stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $395.49, for a total value of $2,252,315.55. Following the completion of the transaction, the chief executive officer now owns 654,656 shares in the company, valued at approximately $258,909,901.44. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO August J. Troendle sold 15,102 shares of Medpace stock in a transaction that occurred on Monday, April 29th. The stock was sold at an average price of $400.69, for a total value of $6,051,220.38. Following the completion of the transaction, the chief executive officer now owns 791,541 shares of the company’s stock, valued at approximately $317,162,563.29. The disclosure for this sale can be found here. Insiders have sold a total of 29,621 shares of company stock valued at $11,816,852 in the last quarter. 20.30% of the stock is currently owned by insiders.

Medpace Stock Performance

NASDAQ:MEDP traded up $0.97 during trading hours on Friday, reaching $381.47. The stock had a trading volume of 473,847 shares, compared to its average volume of 317,691. Medpace Holdings, Inc. has a 52 week low of $227.21 and a 52 week high of $459.77. The company has a 50 day moving average price of $404.32 and a two-hundred day moving average price of $382.76. The stock has a market capitalization of $11.83 billion, a PE ratio of 38.89, a PEG ratio of 1.82 and a beta of 1.36.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, July 22nd. The company reported $2.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.54 by $0.21. Medpace had a return on equity of 55.14% and a net margin of 16.74%. The business had revenue of $528.10 million for the quarter, compared to the consensus estimate of $528.41 million. During the same quarter in the previous year, the company posted $1.93 EPS. The company’s revenue was up 14.6% compared to the same quarter last year. Equities research analysts predict that Medpace Holdings, Inc. will post 11.69 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Deutsche Bank Aktiengesellschaft decreased their price objective on Medpace from $395.00 to $336.00 and set a “hold” rating on the stock in a research note on Wednesday. StockNews.com raised Medpace from a “hold” rating to a “buy” rating in a research note on Tuesday. TD Cowen decreased their target price on Medpace from $452.00 to $434.00 and set a “buy” rating on the stock in a research note on Wednesday. Jefferies Financial Group raised Medpace from a “hold” rating to a “buy” rating and lifted their target price for the company from $340.00 to $450.00 in a research note on Tuesday, April 23rd. Finally, Robert W. Baird decreased their target price on Medpace from $469.00 to $430.00 and set an “outperform” rating on the stock in a research note on Wednesday. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $424.14.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.